Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria
A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the efficacy and safety of mizolastine (M), a new HI-receptor antagonist, as a once-daily 10-g dose in chronic idiopathic urticaria. Fifty-six outpatients (M: n= 28; P: n= 28) with...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Brostoff, J. [verfasserIn] Fitzharris, P. [verfasserIn] Dunmore, C. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Publishing Ltd ; 1996 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2007 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Allergy - Oxford : Blackwell Munksgaard, 1978, 51(1996), 5, Seite 0 |
| Übergeordnetes Werk: |
volume:51 ; year:1996 ; number:5 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1111/j.1398-9995.1996.tb04616.x |
|---|
| Katalog-ID: |
NLEJ239275608 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ239275608 | ||
| 003 | DE-627 | ||
| 005 | 20230505191151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120426s1996 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1398-9995.1996.tb04616.x |2 doi | |
| 035 | |a (DE-627)NLEJ239275608 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Brostoff, J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria |
| 264 | 1 | |a Oxford, UK |b Blackwell Publishing Ltd |c 1996 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the efficacy and safety of mizolastine (M), a new HI-receptor antagonist, as a once-daily 10-g dose in chronic idiopathic urticaria. Fifty-six outpatients (M: n= 28; P: n= 28) with a mean age of 38 ± 15 years, a duration of disease of more than 3 years, and symptoms of urticaria at least twice a week in the absence of treatment were recruited. After a single-blind placebo run-in period, patients were allocated to one of two treatment groups and were evaluated after 7 and 28 days. The main characteristics (age, duration of disease, number of urticarial episodes, and total score) of the two groups were comparable at inclusion. Mizolastine was shown to improve the urticaria symptoms: at the end of the study, mizolastine produced a significantly greater decrease in the global symptom score comprising itch, wheals, and erythema (M: 2.1 ± 2.1 vs P: 0.4 ± 2.0; P = 0.002). The patient-rated global discomfort from symptoms measured by visual analog scale was significantly improved with mizolastine (M: 31.4 ± 36.7) compared to placebo (P: 5.4 ± 27.6; P = 0.003), with respectively more M responders (74.1%) than P responders (28.6%, P = 0.00l), a responder being a patient with a ± 50% decrease in VAS. Premature dropouts due to lack of efficacy and loss to follow-up mainly occurred at the first evaluation (day 7) and were more often observed in patients in the placebo group (n= 17) than in the mizolastine group (n= 8) (P= 0.031). No serious adverse events were recorded. Somnolence was reported in two mizolastine patients, one of whom discontinued the study. Thus, mizolastine may be considered a new treatment option for the symptoms of chronic urticaria. | ||
| 533 | |d 2007 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2007|||||||||| | ||
| 650 | 4 | |a antihistamine | |
| 700 | 1 | |a Fitzharris, P. |e verfasserin |4 aut | |
| 700 | 1 | |a Dunmore, C. |e verfasserin |4 aut | |
| 700 | 1 | |a Theron, M. |4 oth | |
| 700 | 1 | |a Blondin, P. |4 oth | |
| 773 | 0 | 8 | |i In |t Allergy |d Oxford : Blackwell Munksgaard, 1978 |g 51(1996), 5, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243926979 |w (DE-600)2003114-2 |x 1398-9995 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:1996 |g number:5 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1398-9995.1996.tb04616.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 1996 |e 5 |h 0 | ||
| author_variant |
j b jb p f pf c d cd |
|---|---|
| matchkey_str |
article:13989995:1996----::fiayfioatnaeathsaieoprdihlcbiteramno |
| hierarchy_sort_str |
1996 |
| publishDate |
1996 |
| allfields |
10.1111/j.1398-9995.1996.tb04616.x doi (DE-627)NLEJ239275608 DE-627 ger DE-627 rakwb Brostoff, J. verfasserin aut Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria Oxford, UK Blackwell Publishing Ltd 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the efficacy and safety of mizolastine (M), a new HI-receptor antagonist, as a once-daily 10-g dose in chronic idiopathic urticaria. Fifty-six outpatients (M: n= 28; P: n= 28) with a mean age of 38 ± 15 years, a duration of disease of more than 3 years, and symptoms of urticaria at least twice a week in the absence of treatment were recruited. After a single-blind placebo run-in period, patients were allocated to one of two treatment groups and were evaluated after 7 and 28 days. The main characteristics (age, duration of disease, number of urticarial episodes, and total score) of the two groups were comparable at inclusion. Mizolastine was shown to improve the urticaria symptoms: at the end of the study, mizolastine produced a significantly greater decrease in the global symptom score comprising itch, wheals, and erythema (M: 2.1 ± 2.1 vs P: 0.4 ± 2.0; P = 0.002). The patient-rated global discomfort from symptoms measured by visual analog scale was significantly improved with mizolastine (M: 31.4 ± 36.7) compared to placebo (P: 5.4 ± 27.6; P = 0.003), with respectively more M responders (74.1%) than P responders (28.6%, P = 0.00l), a responder being a patient with a ± 50% decrease in VAS. Premature dropouts due to lack of efficacy and loss to follow-up mainly occurred at the first evaluation (day 7) and were more often observed in patients in the placebo group (n= 17) than in the mizolastine group (n= 8) (P= 0.031). No serious adverse events were recorded. Somnolence was reported in two mizolastine patients, one of whom discontinued the study. Thus, mizolastine may be considered a new treatment option for the symptoms of chronic urticaria. 2007 Blackwell Publishing Journal Backfiles 1879-2005 |2007|||||||||| antihistamine Fitzharris, P. verfasserin aut Dunmore, C. verfasserin aut Theron, M. oth Blondin, P. oth In Allergy Oxford : Blackwell Munksgaard, 1978 51(1996), 5, Seite 0 Online-Ressource (DE-627)NLEJ243926979 (DE-600)2003114-2 1398-9995 nnns volume:51 year:1996 number:5 pages:0 http://dx.doi.org/10.1111/j.1398-9995.1996.tb04616.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 51 1996 5 0 |
| spelling |
10.1111/j.1398-9995.1996.tb04616.x doi (DE-627)NLEJ239275608 DE-627 ger DE-627 rakwb Brostoff, J. verfasserin aut Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria Oxford, UK Blackwell Publishing Ltd 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the efficacy and safety of mizolastine (M), a new HI-receptor antagonist, as a once-daily 10-g dose in chronic idiopathic urticaria. Fifty-six outpatients (M: n= 28; P: n= 28) with a mean age of 38 ± 15 years, a duration of disease of more than 3 years, and symptoms of urticaria at least twice a week in the absence of treatment were recruited. After a single-blind placebo run-in period, patients were allocated to one of two treatment groups and were evaluated after 7 and 28 days. The main characteristics (age, duration of disease, number of urticarial episodes, and total score) of the two groups were comparable at inclusion. Mizolastine was shown to improve the urticaria symptoms: at the end of the study, mizolastine produced a significantly greater decrease in the global symptom score comprising itch, wheals, and erythema (M: 2.1 ± 2.1 vs P: 0.4 ± 2.0; P = 0.002). The patient-rated global discomfort from symptoms measured by visual analog scale was significantly improved with mizolastine (M: 31.4 ± 36.7) compared to placebo (P: 5.4 ± 27.6; P = 0.003), with respectively more M responders (74.1%) than P responders (28.6%, P = 0.00l), a responder being a patient with a ± 50% decrease in VAS. Premature dropouts due to lack of efficacy and loss to follow-up mainly occurred at the first evaluation (day 7) and were more often observed in patients in the placebo group (n= 17) than in the mizolastine group (n= 8) (P= 0.031). No serious adverse events were recorded. Somnolence was reported in two mizolastine patients, one of whom discontinued the study. Thus, mizolastine may be considered a new treatment option for the symptoms of chronic urticaria. 2007 Blackwell Publishing Journal Backfiles 1879-2005 |2007|||||||||| antihistamine Fitzharris, P. verfasserin aut Dunmore, C. verfasserin aut Theron, M. oth Blondin, P. oth In Allergy Oxford : Blackwell Munksgaard, 1978 51(1996), 5, Seite 0 Online-Ressource (DE-627)NLEJ243926979 (DE-600)2003114-2 1398-9995 nnns volume:51 year:1996 number:5 pages:0 http://dx.doi.org/10.1111/j.1398-9995.1996.tb04616.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 51 1996 5 0 |
| allfields_unstemmed |
10.1111/j.1398-9995.1996.tb04616.x doi (DE-627)NLEJ239275608 DE-627 ger DE-627 rakwb Brostoff, J. verfasserin aut Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria Oxford, UK Blackwell Publishing Ltd 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the efficacy and safety of mizolastine (M), a new HI-receptor antagonist, as a once-daily 10-g dose in chronic idiopathic urticaria. Fifty-six outpatients (M: n= 28; P: n= 28) with a mean age of 38 ± 15 years, a duration of disease of more than 3 years, and symptoms of urticaria at least twice a week in the absence of treatment were recruited. After a single-blind placebo run-in period, patients were allocated to one of two treatment groups and were evaluated after 7 and 28 days. The main characteristics (age, duration of disease, number of urticarial episodes, and total score) of the two groups were comparable at inclusion. Mizolastine was shown to improve the urticaria symptoms: at the end of the study, mizolastine produced a significantly greater decrease in the global symptom score comprising itch, wheals, and erythema (M: 2.1 ± 2.1 vs P: 0.4 ± 2.0; P = 0.002). The patient-rated global discomfort from symptoms measured by visual analog scale was significantly improved with mizolastine (M: 31.4 ± 36.7) compared to placebo (P: 5.4 ± 27.6; P = 0.003), with respectively more M responders (74.1%) than P responders (28.6%, P = 0.00l), a responder being a patient with a ± 50% decrease in VAS. Premature dropouts due to lack of efficacy and loss to follow-up mainly occurred at the first evaluation (day 7) and were more often observed in patients in the placebo group (n= 17) than in the mizolastine group (n= 8) (P= 0.031). No serious adverse events were recorded. Somnolence was reported in two mizolastine patients, one of whom discontinued the study. Thus, mizolastine may be considered a new treatment option for the symptoms of chronic urticaria. 2007 Blackwell Publishing Journal Backfiles 1879-2005 |2007|||||||||| antihistamine Fitzharris, P. verfasserin aut Dunmore, C. verfasserin aut Theron, M. oth Blondin, P. oth In Allergy Oxford : Blackwell Munksgaard, 1978 51(1996), 5, Seite 0 Online-Ressource (DE-627)NLEJ243926979 (DE-600)2003114-2 1398-9995 nnns volume:51 year:1996 number:5 pages:0 http://dx.doi.org/10.1111/j.1398-9995.1996.tb04616.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 51 1996 5 0 |
| allfieldsGer |
10.1111/j.1398-9995.1996.tb04616.x doi (DE-627)NLEJ239275608 DE-627 ger DE-627 rakwb Brostoff, J. verfasserin aut Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria Oxford, UK Blackwell Publishing Ltd 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the efficacy and safety of mizolastine (M), a new HI-receptor antagonist, as a once-daily 10-g dose in chronic idiopathic urticaria. Fifty-six outpatients (M: n= 28; P: n= 28) with a mean age of 38 ± 15 years, a duration of disease of more than 3 years, and symptoms of urticaria at least twice a week in the absence of treatment were recruited. After a single-blind placebo run-in period, patients were allocated to one of two treatment groups and were evaluated after 7 and 28 days. The main characteristics (age, duration of disease, number of urticarial episodes, and total score) of the two groups were comparable at inclusion. Mizolastine was shown to improve the urticaria symptoms: at the end of the study, mizolastine produced a significantly greater decrease in the global symptom score comprising itch, wheals, and erythema (M: 2.1 ± 2.1 vs P: 0.4 ± 2.0; P = 0.002). The patient-rated global discomfort from symptoms measured by visual analog scale was significantly improved with mizolastine (M: 31.4 ± 36.7) compared to placebo (P: 5.4 ± 27.6; P = 0.003), with respectively more M responders (74.1%) than P responders (28.6%, P = 0.00l), a responder being a patient with a ± 50% decrease in VAS. Premature dropouts due to lack of efficacy and loss to follow-up mainly occurred at the first evaluation (day 7) and were more often observed in patients in the placebo group (n= 17) than in the mizolastine group (n= 8) (P= 0.031). No serious adverse events were recorded. Somnolence was reported in two mizolastine patients, one of whom discontinued the study. Thus, mizolastine may be considered a new treatment option for the symptoms of chronic urticaria. 2007 Blackwell Publishing Journal Backfiles 1879-2005 |2007|||||||||| antihistamine Fitzharris, P. verfasserin aut Dunmore, C. verfasserin aut Theron, M. oth Blondin, P. oth In Allergy Oxford : Blackwell Munksgaard, 1978 51(1996), 5, Seite 0 Online-Ressource (DE-627)NLEJ243926979 (DE-600)2003114-2 1398-9995 nnns volume:51 year:1996 number:5 pages:0 http://dx.doi.org/10.1111/j.1398-9995.1996.tb04616.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 51 1996 5 0 |
| allfieldsSound |
10.1111/j.1398-9995.1996.tb04616.x doi (DE-627)NLEJ239275608 DE-627 ger DE-627 rakwb Brostoff, J. verfasserin aut Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria Oxford, UK Blackwell Publishing Ltd 1996 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the efficacy and safety of mizolastine (M), a new HI-receptor antagonist, as a once-daily 10-g dose in chronic idiopathic urticaria. Fifty-six outpatients (M: n= 28; P: n= 28) with a mean age of 38 ± 15 years, a duration of disease of more than 3 years, and symptoms of urticaria at least twice a week in the absence of treatment were recruited. After a single-blind placebo run-in period, patients were allocated to one of two treatment groups and were evaluated after 7 and 28 days. The main characteristics (age, duration of disease, number of urticarial episodes, and total score) of the two groups were comparable at inclusion. Mizolastine was shown to improve the urticaria symptoms: at the end of the study, mizolastine produced a significantly greater decrease in the global symptom score comprising itch, wheals, and erythema (M: 2.1 ± 2.1 vs P: 0.4 ± 2.0; P = 0.002). The patient-rated global discomfort from symptoms measured by visual analog scale was significantly improved with mizolastine (M: 31.4 ± 36.7) compared to placebo (P: 5.4 ± 27.6; P = 0.003), with respectively more M responders (74.1%) than P responders (28.6%, P = 0.00l), a responder being a patient with a ± 50% decrease in VAS. Premature dropouts due to lack of efficacy and loss to follow-up mainly occurred at the first evaluation (day 7) and were more often observed in patients in the placebo group (n= 17) than in the mizolastine group (n= 8) (P= 0.031). No serious adverse events were recorded. Somnolence was reported in two mizolastine patients, one of whom discontinued the study. Thus, mizolastine may be considered a new treatment option for the symptoms of chronic urticaria. 2007 Blackwell Publishing Journal Backfiles 1879-2005 |2007|||||||||| antihistamine Fitzharris, P. verfasserin aut Dunmore, C. verfasserin aut Theron, M. oth Blondin, P. oth In Allergy Oxford : Blackwell Munksgaard, 1978 51(1996), 5, Seite 0 Online-Ressource (DE-627)NLEJ243926979 (DE-600)2003114-2 1398-9995 nnns volume:51 year:1996 number:5 pages:0 http://dx.doi.org/10.1111/j.1398-9995.1996.tb04616.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 51 1996 5 0 |
| source |
In Allergy 51(1996), 5, Seite 0 volume:51 year:1996 number:5 pages:0 |
| sourceStr |
In Allergy 51(1996), 5, Seite 0 volume:51 year:1996 number:5 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
antihistamine |
| isfreeaccess_bool |
false |
| container_title |
Allergy |
| authorswithroles_txt_mv |
Brostoff, J. @@aut@@ Fitzharris, P. @@aut@@ Dunmore, C. @@aut@@ Theron, M. @@oth@@ Blondin, P. @@oth@@ |
| publishDateDaySort_date |
1996-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243926979 |
| id |
NLEJ239275608 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ239275608</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505191151.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120426s1996 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1398-9995.1996.tb04616.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ239275608</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Brostoff, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the efficacy and safety of mizolastine (M), a new HI-receptor antagonist, as a once-daily 10-g dose in chronic idiopathic urticaria. Fifty-six outpatients (M: n= 28; P: n= 28) with a mean age of 38 ± 15 years, a duration of disease of more than 3 years, and symptoms of urticaria at least twice a week in the absence of treatment were recruited. After a single-blind placebo run-in period, patients were allocated to one of two treatment groups and were evaluated after 7 and 28 days. The main characteristics (age, duration of disease, number of urticarial episodes, and total score) of the two groups were comparable at inclusion. Mizolastine was shown to improve the urticaria symptoms: at the end of the study, mizolastine produced a significantly greater decrease in the global symptom score comprising itch, wheals, and erythema (M: 2.1 ± 2.1 vs P: 0.4 ± 2.0; P = 0.002). The patient-rated global discomfort from symptoms measured by visual analog scale was significantly improved with mizolastine (M: 31.4 ± 36.7) compared to placebo (P: 5.4 ± 27.6; P = 0.003), with respectively more M responders (74.1%) than P responders (28.6%, P = 0.00l), a responder being a patient with a ± 50% decrease in VAS. Premature dropouts due to lack of efficacy and loss to follow-up mainly occurred at the first evaluation (day 7) and were more often observed in patients in the placebo group (n= 17) than in the mizolastine group (n= 8) (P= 0.031). No serious adverse events were recorded. Somnolence was reported in two mizolastine patients, one of whom discontinued the study. Thus, mizolastine may be considered a new treatment option for the symptoms of chronic urticaria.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2007</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2007||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antihistamine</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fitzharris, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dunmore, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Theron, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blondin, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Allergy</subfield><subfield code="d">Oxford : Blackwell Munksgaard, 1978</subfield><subfield code="g">51(1996), 5, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926979</subfield><subfield code="w">(DE-600)2003114-2</subfield><subfield code="x">1398-9995</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:51</subfield><subfield code="g">year:1996</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1398-9995.1996.tb04616.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">51</subfield><subfield code="j">1996</subfield><subfield code="e">5</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Brostoff, J. |
| spellingShingle |
Brostoff, J. misc antihistamine Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria |
| authorStr |
Brostoff, J. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243926979 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1398-9995 |
| topic_title |
Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria antihistamine |
| publisher |
Blackwell Publishing Ltd |
| publisherStr |
Blackwell Publishing Ltd |
| topic |
misc antihistamine |
| topic_unstemmed |
misc antihistamine |
| topic_browse |
misc antihistamine |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m t mt p b pb |
| hierarchy_parent_title |
Allergy |
| hierarchy_parent_id |
NLEJ243926979 |
| hierarchy_top_title |
Allergy |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243926979 (DE-600)2003114-2 |
| title |
Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria |
| ctrlnum |
(DE-627)NLEJ239275608 |
| title_full |
Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria |
| author_sort |
Brostoff, J. |
| journal |
Allergy |
| journalStr |
Allergy |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1996 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Brostoff, J. Fitzharris, P. Dunmore, C. |
| container_volume |
51 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Brostoff, J. |
| doi_str_mv |
10.1111/j.1398-9995.1996.tb04616.x |
| author2-role |
verfasserin |
| title_sort |
efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria |
| title_auth |
Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria |
| abstract |
A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the efficacy and safety of mizolastine (M), a new HI-receptor antagonist, as a once-daily 10-g dose in chronic idiopathic urticaria. Fifty-six outpatients (M: n= 28; P: n= 28) with a mean age of 38 ± 15 years, a duration of disease of more than 3 years, and symptoms of urticaria at least twice a week in the absence of treatment were recruited. After a single-blind placebo run-in period, patients were allocated to one of two treatment groups and were evaluated after 7 and 28 days. The main characteristics (age, duration of disease, number of urticarial episodes, and total score) of the two groups were comparable at inclusion. Mizolastine was shown to improve the urticaria symptoms: at the end of the study, mizolastine produced a significantly greater decrease in the global symptom score comprising itch, wheals, and erythema (M: 2.1 ± 2.1 vs P: 0.4 ± 2.0; P = 0.002). The patient-rated global discomfort from symptoms measured by visual analog scale was significantly improved with mizolastine (M: 31.4 ± 36.7) compared to placebo (P: 5.4 ± 27.6; P = 0.003), with respectively more M responders (74.1%) than P responders (28.6%, P = 0.00l), a responder being a patient with a ± 50% decrease in VAS. Premature dropouts due to lack of efficacy and loss to follow-up mainly occurred at the first evaluation (day 7) and were more often observed in patients in the placebo group (n= 17) than in the mizolastine group (n= 8) (P= 0.031). No serious adverse events were recorded. Somnolence was reported in two mizolastine patients, one of whom discontinued the study. Thus, mizolastine may be considered a new treatment option for the symptoms of chronic urticaria. |
| abstractGer |
A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the efficacy and safety of mizolastine (M), a new HI-receptor antagonist, as a once-daily 10-g dose in chronic idiopathic urticaria. Fifty-six outpatients (M: n= 28; P: n= 28) with a mean age of 38 ± 15 years, a duration of disease of more than 3 years, and symptoms of urticaria at least twice a week in the absence of treatment were recruited. After a single-blind placebo run-in period, patients were allocated to one of two treatment groups and were evaluated after 7 and 28 days. The main characteristics (age, duration of disease, number of urticarial episodes, and total score) of the two groups were comparable at inclusion. Mizolastine was shown to improve the urticaria symptoms: at the end of the study, mizolastine produced a significantly greater decrease in the global symptom score comprising itch, wheals, and erythema (M: 2.1 ± 2.1 vs P: 0.4 ± 2.0; P = 0.002). The patient-rated global discomfort from symptoms measured by visual analog scale was significantly improved with mizolastine (M: 31.4 ± 36.7) compared to placebo (P: 5.4 ± 27.6; P = 0.003), with respectively more M responders (74.1%) than P responders (28.6%, P = 0.00l), a responder being a patient with a ± 50% decrease in VAS. Premature dropouts due to lack of efficacy and loss to follow-up mainly occurred at the first evaluation (day 7) and were more often observed in patients in the placebo group (n= 17) than in the mizolastine group (n= 8) (P= 0.031). No serious adverse events were recorded. Somnolence was reported in two mizolastine patients, one of whom discontinued the study. Thus, mizolastine may be considered a new treatment option for the symptoms of chronic urticaria. |
| abstract_unstemmed |
A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the efficacy and safety of mizolastine (M), a new HI-receptor antagonist, as a once-daily 10-g dose in chronic idiopathic urticaria. Fifty-six outpatients (M: n= 28; P: n= 28) with a mean age of 38 ± 15 years, a duration of disease of more than 3 years, and symptoms of urticaria at least twice a week in the absence of treatment were recruited. After a single-blind placebo run-in period, patients were allocated to one of two treatment groups and were evaluated after 7 and 28 days. The main characteristics (age, duration of disease, number of urticarial episodes, and total score) of the two groups were comparable at inclusion. Mizolastine was shown to improve the urticaria symptoms: at the end of the study, mizolastine produced a significantly greater decrease in the global symptom score comprising itch, wheals, and erythema (M: 2.1 ± 2.1 vs P: 0.4 ± 2.0; P = 0.002). The patient-rated global discomfort from symptoms measured by visual analog scale was significantly improved with mizolastine (M: 31.4 ± 36.7) compared to placebo (P: 5.4 ± 27.6; P = 0.003), with respectively more M responders (74.1%) than P responders (28.6%, P = 0.00l), a responder being a patient with a ± 50% decrease in VAS. Premature dropouts due to lack of efficacy and loss to follow-up mainly occurred at the first evaluation (day 7) and were more often observed in patients in the placebo group (n= 17) than in the mizolastine group (n= 8) (P= 0.031). No serious adverse events were recorded. Somnolence was reported in two mizolastine patients, one of whom discontinued the study. Thus, mizolastine may be considered a new treatment option for the symptoms of chronic urticaria. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
5 |
| title_short |
Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria |
| url |
http://dx.doi.org/10.1111/j.1398-9995.1996.tb04616.x |
| remote_bool |
true |
| author2 |
Fitzharris, P. Dunmore, C. Theron, M. Blondin, P. |
| author2Str |
Fitzharris, P. Dunmore, C. Theron, M. Blondin, P. |
| ppnlink |
NLEJ243926979 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1111/j.1398-9995.1996.tb04616.x |
| up_date |
2024-07-06T07:05:03.020Z |
| _version_ |
1803812342879748096 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ239275608</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505191151.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120426s1996 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1398-9995.1996.tb04616.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ239275608</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Brostoff, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the efficacy and safety of mizolastine (M), a new HI-receptor antagonist, as a once-daily 10-g dose in chronic idiopathic urticaria. Fifty-six outpatients (M: n= 28; P: n= 28) with a mean age of 38 ± 15 years, a duration of disease of more than 3 years, and symptoms of urticaria at least twice a week in the absence of treatment were recruited. After a single-blind placebo run-in period, patients were allocated to one of two treatment groups and were evaluated after 7 and 28 days. The main characteristics (age, duration of disease, number of urticarial episodes, and total score) of the two groups were comparable at inclusion. Mizolastine was shown to improve the urticaria symptoms: at the end of the study, mizolastine produced a significantly greater decrease in the global symptom score comprising itch, wheals, and erythema (M: 2.1 ± 2.1 vs P: 0.4 ± 2.0; P = 0.002). The patient-rated global discomfort from symptoms measured by visual analog scale was significantly improved with mizolastine (M: 31.4 ± 36.7) compared to placebo (P: 5.4 ± 27.6; P = 0.003), with respectively more M responders (74.1%) than P responders (28.6%, P = 0.00l), a responder being a patient with a ± 50% decrease in VAS. Premature dropouts due to lack of efficacy and loss to follow-up mainly occurred at the first evaluation (day 7) and were more often observed in patients in the placebo group (n= 17) than in the mizolastine group (n= 8) (P= 0.031). No serious adverse events were recorded. Somnolence was reported in two mizolastine patients, one of whom discontinued the study. Thus, mizolastine may be considered a new treatment option for the symptoms of chronic urticaria.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2007</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2007||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antihistamine</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fitzharris, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dunmore, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Theron, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blondin, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Allergy</subfield><subfield code="d">Oxford : Blackwell Munksgaard, 1978</subfield><subfield code="g">51(1996), 5, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926979</subfield><subfield code="w">(DE-600)2003114-2</subfield><subfield code="x">1398-9995</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:51</subfield><subfield code="g">year:1996</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1398-9995.1996.tb04616.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">51</subfield><subfield code="j">1996</subfield><subfield code="e">5</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.400196 |